Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in …
NL Albert, M Weller, B Suchorska, N Galldiks… - Neuro …, 2016 - academic.oup.com
This guideline provides recommendations for the use of PET imaging in gliomas. The review
examines established clinical benefit in glioma patients of PET using glucose (18F-FDG) …
examines established clinical benefit in glioma patients of PET using glucose (18F-FDG) …
Metabolic positron emission tomography imaging in cancer detection and therapy response
Positron emission tomography (PET) is a noninvasive imaging technique that provides a
functional or metabolic assessment of normal tissue or disease conditions. Fluorine 18 …
functional or metabolic assessment of normal tissue or disease conditions. Fluorine 18 …
Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors
C Juhász, S Dwivedi, DO Kamson… - Molecular …, 2014 - journals.sagepub.com
Positron emission tomography (PET) is an imaging technology that can detect and
characterize tumors based on their molecular and biochemical properties, such as altered …
characterize tumors based on their molecular and biochemical properties, such as altered …
Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas
BJ Fueger, J Czernin, T Cloughesy… - Journal of Nuclear …, 2010 - Soc Nuclear Med
6-18F-fluoro-l-dopa (18F-FDOPA) measured with PET as a biomarker of amino acid uptake
has been investigated in brain tumor imaging. The aims of the current study were to …
has been investigated in brain tumor imaging. The aims of the current study were to …
The role of LAT1 in 18F-DOPA uptake in malignant gliomas
RS Youland, GJ Kitange, TE Peterson… - Journal of neuro …, 2013 - Springer
Positron emission tomography (PET) imaging with the amino acid tracer 6-18 F-fluoro-l-3, 4-
dihydroxy-phenylalanine (18 F-DOPA) may provide better spatial and functional information …
dihydroxy-phenylalanine (18 F-DOPA) may provide better spatial and functional information …
Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
J Schwarzenberg, J Czernin, TF Cloughesy… - Clinical Cancer …, 2014 - AACR
Purpose: This study compares the value of 3, 4-dihydroxy-6-[18F]-fluoro-l-phenylalanine
(18F-FDOPA) positron emission tomography (PET) and MRI in assessing outcome during …
(18F-FDOPA) positron emission tomography (PET) and MRI in assessing outcome during …
[HTML][HTML] Positron emission tomography (PET)/computed tomography (CT) imaging in radiation therapy treatment planning: a review of PET imaging tracers and …
Purpose Positron emission tomography (PET)/computed tomography (CT) has become a
critical tool in clinical oncology with an expanding role in guiding radiation treatment …
critical tool in clinical oncology with an expanding role in guiding radiation treatment …
18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT
S Karunanithi, P Sharma, A Kumar… - European journal of …, 2013 - Springer
Purpose Differentiation between recurrence and radiation necrosis in patients with glioma is
crucial, since the two entities have completely different management and prognosis. The …
crucial, since the two entities have completely different management and prognosis. The …
18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab
RJ Harris, TF Cloughesy, WB Pope… - Neuro …, 2012 - academic.oup.com
The current study examined the use of voxel-wise changes in 18F-FDOPA and 18F-FLT PET
uptake, referred to as parametric response maps (PRMs), to determine whether they were …
uptake, referred to as parametric response maps (PRMs), to determine whether they were …